Associate Professor Colm Keane
Principal Research Fellow
Frazer Institute
+61 7 344 37912
Researcher biography
Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.
Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.
Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.
The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.
Book Chapter
Keane, Colm, Nourse, Jamie P. and Gandhi, Maher K. (2012). Rituximab induced late-onset neutropenia. Rituximab: Pharmacology, Clinical Uses and Health Effects. (pp. 93-102) Hauppauge, NY United States: Nova Science Publishers.
Journal Articles
Dierickx, Daan, Keane, Colm and Natkunam, Yasodha (2024). Genetic and immunological features of immune deficiency and dysregulation‐associated lymphoproliferations and lymphomas as a basis for classification. Histopathology. doi: 10.1111/his.15342
Maakaron, Joeseph, Asch, Adam S, Popplewell, Leslie, Collins, Graham P., Flinn, Ian W, Ghosh, Nilanjan, Keane, Colm, Ku, Matthew, Mehta, Amitkumar, Roschewski, Mark, Hacohen-Kleiman, Gal, Huo, Yanan, Zhang, Yi, Renard, Camille, Smith, Sonali M and Advani, Ranjana H (2024). Magrolimab Plus Rituximab with/without Chemotherapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood Advances, 8 (22), 5864-5874. doi: 10.1182/bloodadvances.2024013338
Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Snell, Cameron, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Shanavas, Mohamed, Blyth, Emily, Steidl, Christian, Savage, Kerry, Farinha, Pedro ... Gandhi, Maher K. (2024). Intra‐tumoral and peripheral blood TIGIT and PD ‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology, 99 (11), 2096-2107. doi: 10.1002/ajh.27459
Wight, Joel, Blombery, Piers, Lickiss, Jennifer, Burgess, Melinda, Gould, Clare, Minson, Adrian, Swain, Fiona, Sabdia, Muhammed B., Gandhi, Maher K., Birchley, Andrew, Keane, Colm and Hawkes, Eliza A (2024). Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance. Haematologica, 109 (9), 3013-3018. doi: 10.3324/haematol.2023.284600
Barraclough, Allison, Agrawal, Shivam, Talaulikar, Dipti, Chong, Geoffrey, Yoo, Edward, Cheah, Chan Y., Franco, Nunzio, Nguyen, Bianca, Mutsando, Howard, Tahir, Fatima, Trotman, Judith, Huang, Jing, Keane, Colm, Lincoln, Mitchel, Cochrane, Tara, Johnston, Anna M., Dickinson, Michael, Opat, Stephen, McQuilten, Zoe K., Wood, Erica M., St George, Gayathri and Hawkes, Eliza A. (2024). Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica, 109 (10), 3338-3345. doi: 10.3324/haematol.2023.284538
Shaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan Y, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoffrey, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A. (2024). Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. eJHaem, 5 (2), 325-332. doi: 10.1002/jha2.870
Bednarska, Karolina, Chowdhury, Rakin, Tobin, Joshua W. D., Swain, Fiona, Keane, Colm, Boyle, Stephen, Khanna, Rajiv and Gandhi, Maher K. (2024). Epstein–Barr virus‐associated lymphomas decoded. British Journal of Haematology, 204 (2), 415-433. doi: 10.1111/bjh.19255
Alim, Louisa F., Keane, Colm and Souza-Fonseca-Guimaraes, Fernando (2024). Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Current Opinion in Immunology, 86 102409. doi: 10.1016/j.coi.2023.102409
Martynchyk, Arina, Chowdhury, Rakin, Hawkes, Eliza A. and Keane, Colm (2023). Prognostic markers within the tumour microenvironment in classical Hodgkin lymphoma. Cancers, 15 (21) 5217, 1-21. doi: 10.3390/cancers15215217
Cass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007
Bonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.13993
Gandhi, Maher K. and Keane, Colm (2023). Expanding the bacterial origins of nodular lymphocyte predominant Hodgkin lymphoma. Haematologica, 108 (12), 3195-3196. doi: 10.3324/haematol.2023.283392
Burgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631
George, Hannah, Gunawardana, Jay, Keane, Colm, Hicks, Rod J. and Gandhi, Maher K. (2023). A coordinated strategy for a simple, pragmatic approach to the early identification of the ultra‐high‐risk patient with diffuse large B‐cell lymphoma. Internal Medicine Journal, 53 (7), 1105-1109. doi: 10.1111/imj.16078
Nguyen, James, Wellard, Cameron, Chung, Eliza, Cheah, Chan Y., Dickinson, Michael, Doo, Nicole Wong, Keane, Colm, Talaulikar, Dipti, Berkahn, Leanne, Morgan, Susan, Hamad, Nada, Cochrane, Tara, Johnston, Anna M., Forsyth, Cecily, Opat, Stephen, Barraclough, Allison, Mutsando, Howard, Ratnasingam, Sumita, Giri, Pratyush, Wood, Erica M., McQuilten, Zoe K. and Hawkes, Eliza A. (2023). Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. European Journal of Haematology, 110 (4), 386-395. doi: 10.1111/ejh.13915
Agrawal, Prashasti, David, Kevin A., Chen, Zhengming, Sundaram, Suchitra, Kim, Seo-Hyun, Vaca, Ryan, Lin, Yong, Singer, Samuel, Malecek, Mary-Kate, Carter, Jordan, Zayac, Adam, Kim, Myung Sun, Reddy, Nishitha, Ney, Douglas, Habib, Alma, Strouse, Christopher, Graber, Jerome, Bachanova, Veronika, Salman, Sidra, Vendiola, Jean A., Hossain, Nasheed, Tsang, Mazie, Major, Ajay, Gandhi, Maher K., Keane, Colm, Bond, David A., Folstad, Matthew, Chang, Julie, Mier-Hicks, Angel ... Martin, Peter (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64 (5), 1026-1034. doi: 10.1080/10428194.2023.2191152
Manos, Kate, Chong, Geoffrey, Keane, Colm, Lee, Sze-Ting, Smith, Charmaine, Churilov, Leonid, McKendrick, Joseph, Renwick, William, Blombery, Piers, Burgess, Melinda, Nelson, Niles Elizabeth, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Scott, Andrew M., Barraclough, Allison, Wight, Joel, Grigg, Andrew, Fong, Chun Yew and Hawkes, Eliza A. (2023). Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. Leukemia, 37 (5), 1092-1102. doi: 10.1038/s41375-023-01863-7
Baggio, Diva, Wellard, Cameron, Chung, Eliza, Talaulikar, Dipti, Keane, Colm, Opat, Stephen, Giri, Pratyush, Minson, Adrian, Cheah, Chan Yoon, Armytage, Tasman, Lee, Denise, Chong, Geoffrey, Johnston, Anna, Cochrane, Tara, Waters, Neil, Hamad, Nada, Wood, Erica M. and Hawkes, Eliza A. (2022). Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leukemia & Lymphoma, 64 (3), 621-627. doi: 10.1080/10428194.2022.2157676
Lymphoma and Related Diseases Registry Investigators, Gandhi, Maher K. and Keane, Colm (2022). Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology, 22 (1) 266, 1-10. doi: 10.1186/s12874-022-01728-0
Keane, Colm, Hamad, Nada, Barraclough, Allison, Lee, Yoo Y., Talaulikar, Dipti, Ku, Matthew, Wight, Joel, Tatarczuch, Maciej, Swain, Fiona and Gregory, Gareth P. (2022). Diagnosis and management of primary central nervous system lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 52 (9), 1624-1632. doi: 10.1111/imj.15658
Gandhi, Maher K and Keane, Colm (2022). CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Haematologica, 108 (4), 1-3. doi: 10.3324/haematol.2022.281440
Shanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351
Keane, Colm, Coalter, Matthew and Martin-Loeches, Ignacio (2021). Immune system disequilibrium-neutrophils, their extracellular traps, and COVID-19-induced sepsis. Frontiers in Medicine, 8 711397, 1-12. doi: 10.3389/fmed.2021.711397
Proctor, Martina, Gonzalez Cruz, Jazmina L., Daignault-Mill, Sheena M., Veitch, Margaret, Zeng, Bijun, Ehmann, Anna, Sabdia, Muhammed, Snell, Cameron, Keane, Colm, Dolcetti, Riccardo, Haass, Nikolas K., Wells, James W. and Gabrielli, Brian (2021). Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers, 13 (15) 3733, 1-19. doi: 10.3390/cancers13153733
Nath, Karthik, Law, Soi-Cheng, Sabdia, Muhammed B., Gunawardana, Jay, de Long, Lilia M., Sester, David, Shanavas, Mohamed, Tsang, Hennes, Tobin, Joshua W. D., Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Jain, Sanjiv, Keane, Colm, Talaulikar, Dipti, Trotman, Judith, Law, Phillip and Gandhi, Maher K. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 5 (12), 2644-2649. doi: 10.1182/bloodadvances.2020004051
Law, Soi C., Hoang, Thanh, O'Rourke, Kacey, Tobin, Joshua W. D., Gunawardana, Jay, Loo‐Oey, Dorothy, Bednarska, Karolina, Merida de Long, Lilia, Sabdia, Muhammed B., Hapgood, Greg, Blyth, Emily, Clancy, Leighton, Hennig, Stefanie, Keane, Colm and Gandhi, Maher K. (2021). Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 21 (10) ajt.16628, 3465-3471. doi: 10.1111/ajt.16628
Tobin, Joshua W. D., Bednarska, Karolina, Campbell, Ashlea and Keane, Colm (2021). PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphoma. Cells, 10 (5) 1152, 1-23. doi: 10.3390/cells10051152
Gandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520
Keane, Colm, Law, Soi C., Gould, Clare, Birch, Simone, Sabdia, Muhammed B., Merida de Long, Lilia, Thillaiyampalam, Gayathri, Abro, Emad, Tobin, Joshua W., Tan, Xiaohong, Xu-Monette, Zijun Y., Young, Ken H., Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Gill, Anthony, Talaulikar, Dipti, Jain, Sanjiv, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Cross, Donna, Hertzberg, Mark and Gandhi, Maher K. (2020). LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 4 (7), 1367-1377. doi: 10.1182/bloodadvances.2019001390
Tobin, Joshua W.D., Keane, Colm, Gunawardana, Jay and Gandhi, Maher K. (2020). Reply to M. Sorigue. Journal of Clinical Oncology, 38 (6), 648-649. doi: 10.1200/JCO.19.02935
Cristino, Alexandre S., Nourse, Jamie, West, Rachael A., Sabdia, Muhammed Bilal, Law, Soi C., Gunawardana, Jay, Vari, Frank, Mujaj, Sally, Thillaiyampalam, Gayathri, Snell, Cameron, Gough, Madeline, Keane, Colm and Gandhi, Maher K. (2019). EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2. Blood, 134 (25), 2261-2270. doi: 10.1182/blood.2019000889
Wight, Joel C., Yue, Mimi, Keane, Colm, Johnston, Anna, Linton, Kim, Chin, Collin, Wai, Shin Hnin, Talaulikar, Dipti, Gasiorowski, Robin, Yoon Cheah, Chan, Gregory, Gareth P., Dickinson, Michael, Minson, Adrian, Coombes, Caitlin, Ku, Matthew, Lam, Stephanie and Hawkes, Eliza A. (2019). Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology, 187 (2) bjh.16064, 174-184. doi: 10.1111/bjh.16064
Keane, Colm, Tobin, Joshua, Gunawardana, Jay, Francis, Santiyagu, Gifford, Grace, Gabrielli, Sara, Gill, Anthony, Stevenson, William, Talaulikar, Dipti, Gould, Clare, Jain, Sanjiv, Birch, Simone, Hertzberg, Mark and Gandhi, Maher K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103 (3) ejh.13274, 200-207. doi: 10.1111/ejh.13274
Tobin, Joshua W. D., Keane, Colm, Gunawardana, Jay, Mollee, Peter, Birch, Simone, Hoang, Thanh, Lee, Justina, Li, Li, Huang, Li, Murigneux, Valentine, Fink, J. Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu, Kridel, Robert, Weigert, Oliver, Haebe, Sarah, Jurinovic, Vindi, Klapper, Wolfram, Steidl, Christian, Sehn, Laurie H., Law, Soi-Cheng, Wykes, Michelle N. and Gandhi, Maher K. (2019). Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration. Journal of Clinical Oncology, 37 (34), 3300-3309. doi: 10.1200/JCO.18.02365
Lees, Charlotte, Keane, Colm, Gandhi, Maher K. and Gunawardana, Jay (2019). Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. British Journal of Haematology, 185 (1), 25-41. doi: 10.1111/bjh.15778
Law, Soi Cheng, Haigh, Oscar L., Walpole, Carina M., Keane, Colm, Miles, John, Gandhi, Maher K., Radford, Kristen J. and Steptoe, Raymond J. (2019). Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies. Journal of Immunological Methods, 465, 72-76. doi: 10.1016/j.jim.2018.12.002
Keane, Colm and Yoon Cheah, Chan (2019). Designing optimal prognostic models for diffuse large B-cell lymphoma. Leukemia and Lymphoma, 60 (8), 1-3. doi: 10.1080/10428194.2019.1599117
Cui, Qingyan, Vari, Frank, Cristino, Alexandre S., Salomon, Carlos, Rice, Gregory E., Sabdia, Muhammed B., Guanzon, Dominic, Palma, Carlos, Mathew, Marina, Talaulikar, Dipti, Jain, Sanjiv, Han, Erica, Hertzberg, Mark S., Gould, Clare, Crooks, Pauline, Thillaiyampalam, Gayathri, Keane, Colm and Gandhi, Maher K. (2018). Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large b-cell lymphoma. Oncotarget, 9 (78), 34644-34657. doi: 10.18632/oncotarget.26141
Keane, Colm, Tobin, Joshua, Talaulikar, Dipti, Green, Michael, Crooks, Pauline, Jain, Sanjiv and Gandhi, Maher (2018). A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. OncoTarget, 9 (34), 23620-23627. doi: 10.18632/oncotarget.25306
Vari, Frank, Arpon, David, Keane, Colm, Hertzberg, Mark S, Talaulikar, Dipti, Jain, Sanjiv, Cui, Qingyan, Han, Erica, Tobin, Josh, Bird, Robert, Cross, Donna, Hernandez, Annette, Gould, Clare, Birch, Simone and Gandhi, Maher K (2018). Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood, 131 (16), 1809-1819. doi: 10.1182/blood-2017-07-796342
McKee, Sara J., Tuong, Zewen K., Kobayashi, Takumi, Doff, Brianna L., Soon, Megan S. F ., Nissen, Michael, Lam, Pui Yeng, Keane, Colm, Vari, Frank, Moi, Davide, Mazzieri, Roberta, Leggatt, Graham, Gandhi, Maher K. and Mattarollo, Stephen R. (2018). B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. OncoImmunology, 7 (2) e1393599, e1393599. doi: 10.1080/2162402X.2017.1393599
Keane, Colm, Jerkic, Mirjana and Laffey, John G. (2017). Stem cell-based therapies for sepsis. Anesthesiology, 127 (6), 1017-1034. doi: 10.1097/ALN.0000000000001882
Keane, Colm, Gould, Clare, Jones, Kimberley, Hamm, David, Talaulikar, Dipti, Ellis, Jonathan, Vari, Frank, Birch, Simone, Han, Erica, Wood, Peter, Le-Cao, Kim-Anh, Green, Michael R., Crooks, Pauline, Jain, Sanjiv, Tobin, Josh, Steptoe, Raymond J. and Gandhi, Maher K. (2017). The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma. Clinical Cancer Research, 23 (7), 1820-1828. doi: 10.1158/1078-0432.CCR-16-1576
Jones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R. and Gandhi, M. K. (2016). The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma. Clinical and Experimental Immunology, 183 (2), 206-220. doi: 10.1111/cei.12716
Jivan, Yatika, Peach, Betsy and Keane, Colm (2015). Copy-number variation and false positive results of prenatal screening. The New England Journal of Medicine, 373 (26), 2584-2585. doi: 10.1056/NEJMc1507106
Kingsley, Christopher, Wang, Eric, Oliphant, Arnold, Van Den Boom, Dirk, Ehrich, Mathias, Kim, Sung K., Jivan, Yatika, Peach, Betsy, Keane, Colm, Snyder, Matthew W., Gammill, Hilary S. and Shendure, Jay (2015). Copy-number variation and false positive results of prenatal screening. New England Journal of Medicine, 373 (26), 2583-2585. doi: 10.1056/NEJMc1507106
Keane, Colm, Vari, Frank, Hertzberg, Mark, Le Cao, Kim-Anh, Green, Michael R., Han, Erica, Seymour, John F., Hicks, Rodney J., Gill, Devinder, Crooks, Pauline, Gould, Clare, Jones, Kimberley, Griffiths, Lyn R., Talaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematology, 2 (10), e445-e455. doi: 10.1016/S2352-3026(15)00150-7
Kurtz, David M., Green, Michael R., Bratman, Scott V., Scherer, Florian, Liu, Chih Long, Kunder, Christian A., Takahashi, Kazuhiro, Glover, Cynthia, Keane, Colm, Kihira, Shingo, Visser, Brendan, Callahan, Jason, Kong, Katherine A., Faham, Malek, Corbelli, Karen S., Miklos, David, Advani, Ranjana H., Levy, Ronald, Hicks, Rodney J., Hertzberg, Mark, Ohgami, Robert S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125 (24), 3679-3687. doi: 10.1182/blood-2015-03-635169
Fink, S. E. K., Gandhi, M. K., Nourse, J. P., Keane, C., Jones, K., Crooks, P., Johrens, K., Korfel, A., Schmidt, H., Neumann, S., Tiede, A., Jager, U., Duhrsen, U., Neuhaus, R., Dreyling, M., Borchert, K., Sudhoff, T., Riess, H., Anagnostopoulos, I. and Trappe, R. U. (2014). A comprehensive analysis of the cellular and EBV-Specific MicroRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors. American Journal of Transplantation, 14 (11), 2577-2587. doi: 10.1111/ajt.12858
Jones, Kimberley, Nourse, Jamie P., Keane, Colm, Bhatnagar, Atul and Gandhi, Maher K. (2014). Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 20 (1), 253-264. doi: 10.1158/1078-0432.CCR-13-1024
Keane, Colm, Gill, Devinder, Vari, Frank, Cross, Donna, Griffiths, Lynn and Gandhi, Maher (2013). CD4+Tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. American Journal of Hematology, 88 (4), 273-276. doi: 10.1002/ajh.23398
Jones, Kimberley, Vari, Frank, Keane, Colm, Crooks, Pauline, Nourse, Jamie P., Seymour, Louise A., Gottlieb, David, Ritchie, David, Gill, Devinder and Gandhi, Maher K. (2013). Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma. Clinical Cancer Research, 19 (3), 731-742. doi: 10.1158/1078-0432.CCR-12-2693
Aya-Bonilla, C., Green, M.R., Camilleri, E., Benton, M., Keane, C., Marlton, P., Lea, R., Gandhi, M.K. and Griffiths, L.R. (2013). High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to non-hodgkin's lymphoma. Genes Chromosomes and Cancer, 52 (5), 467-479. doi: 10.1002/gcc.22044
Keane, C., Nourse, J. P., Crooks, P., Nguyen-Van, D., Mutsando, H., Mollee, P., Lea, R. A. and Gandhi, M. K. (2012). Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. Internal Medicine Journal, 42 (10), 1113-1119. doi: 10.1111/j.1445-5994.2011.02587.x
Nourse, J.P., Crooks, P., Keane, C.., Nguyen-Van, D., Mujaj, S., Ross, N., Jones, K., Vari, F., Han, E., Trappe, R., Fink, S. and Gandhi, M.K. (2012). Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samples. Journal of Virological Methods, 184 (1-2), 46-54. doi: 10.1016/j.jviromet.2012.05.005
Lane, Steven, Gill, Devinder, McMillan, Nigel A. J., Saunders, Nicholas, Murphy, Rachel, Spurr, Terrence, Keane, Colm, Fan, Helen Mar and Mollee, Peter (2012). Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia & Lymphoma, 53 (6), 1077-1083. doi: 10.3109/10428194.2011.642302
Jones, Kimberley, Nourse, Jamie P., Keane, Colm, Crooks, Pauline, Gottlieb, David, Ritchie, David S., Gill, Devinder and Gandhi, Maher K. (2012). Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. American Journal of Hematology, 87 (3), 258-265. doi: 10.1002/ajh.22252
Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159.
Keane, Colm, Mollee, Peter, Marlton, Paula and Gill, Devinder (2011). Treatment of acute promyelocytic leukaemia in the Jehovah's Witness population. Annals of Hematology, 90 (3), 359-360. doi: 10.1007/s00277-010-1023-0
Keane, Colm, Henden, Andrea, Mills, Tony and Wood, Peter (2009). Myeloid and lymphoid neoplasm with FGFR1 abnormality. British Journal of Haematology, 145 (4), 440-440. doi: 10.1111/j.1365-2141.2008.07480.x
Keane, Colm, Henden, Andrea and Bird, Robert (2009). Catastrophic tumour lysis syndrome following single dose of imatinib. European Journal of Haematology, 82 (3), 244-245. doi: 10.1111/j.1600-0609.2008.01186.x
Keane, Colm, Colreavy, Michael, Lynch, Maureen and O'Gorman, Peter (2009). Aspergillus flavus sinusitis in ALL. American Journal of Hematology, 84 (2), 123-123. doi: 10.1002/ajh.21167
Keane, Colm, Prout, Barry and Bird, Robert (2008). Neutrophil phagocytosis of Klebsiella pneumoniae. British Journal of Haematology, 142 (5), 682-682. doi: 10.1111/j.1365-2141.2008.07213.x
Keane, C. and Gill, D. (2008). Multi-organ involvement with crystal-storing histiocytosis. British Journal of Haematology, 141 (6), 750-750. doi: 10.1111/j.1365-2141.2008.07131.x
Keane, Colm, Gibbs, Simon, Seymour, John F., Mills, Anthony K ., Grimmett, Karen, Van Kuilenberg, Rosita, Russell, Saal, Gill, Devinder, Prince, H. Miles, Marlton, Paula and Mollee, Peter (2006). The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 24 (3), 159-163. doi: 10.1002/hon.784
Conference Papers
Chong, Geoffrey, Palmer, Jodie, Barraclough, Allison, Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza Anne (2024). First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.tps7092
Chong, Geoffrey, Lee, Denise, Lee, Sze Ting, Grobler, Anneke, Khor, Richard, Campbell, Belinda A., Thachil, Thanuja, Manos, Kate, Martynchyk, Arina, Douglas, Genevieve, Keane, Colm, Palmer, Jodie and Hawkes, Eliza Anne (2024). First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7070
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Peter, Borchmann, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Torzan, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7056
Timmerman, John, Lavie, David, Peter, Borchmann, Gregory, Gareth P., Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, West, Rachel Marceau, Pillai, Pallavi, Marinello, Patricia and Johnson, Nathalie A. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.7055
Chong, Geoff, Palmer, Jodie B., Barraclough, Allison A., Churilov, Leonid, Keane, Colm, Lee, Sze Ting, Lee, Denise, Ratnasingam, Sumita, Smith, Charmaine and Hawkes, Eliza A. (2023). Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-173110
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182019
Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-182128
Timmerman, John, Lavie, David, Johnson, Nathalie, Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Luigi Zinzani, Pier, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex F. (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma After Anti–PD-1 Treatment. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971168.59900.67
Johnson, Nathalie, Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Marceau West, Rachel, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2023). Updated Results From An Open-label Phase 1/2 Study Of Favezelimab In Combination With Pembrolizumab In Patients With Anti–PD-1–naive Relapsed Or Refractory Classical Hodgkin Lymphoma. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971156.02746.02
Shaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoff, Lee, Denise, Manos, Kate, Keane, Colm, Wallwork, Stephanie, Opat, Stephen and Hawkes, Eliza A (2023). Polatuzumab, Bendamustine & Rituximab (POLA-BR) Efficacy In Relapsed/refractory Diffuse Large B Cell Lymphoma (RRDLBCL) Trial-ineligible Patients: An Australian Lymphoma Registry (LARDR) Study. EHA2023, Online, 8 - 15 June 2023. Ovid Technologies (Wolters Kluwer Health). doi: 10.1097/01.hs9.0000971668.24670.ab
Koldej, Rachel, Barraclough, Allison, Ting Lee, Sze, Morgan, Huw, Holzwart, Nicholas, Koshy, Minu, Smith, Charmaine, Chong, Geoff, Gilbertson, Michael, Keane, Colm, Ting, Stephen, Churilov, Leonid, Ritchie, David and Hawkes, Eliza A. (2023). T Cell CD62L Expression Following Nivolumab Therapy Is Associated With Long Term Response To Rituximab-nivolumab In Treatment Naïve Follicular Lymphoma: Results From The 1st Flor Study. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000971812.42966.2d
Swain, F., Burgess, M., Kempe, S., Sabdia, M., Wight, J., Hawkes, E., Mutsando, H., Talaulikar, D., Merida de Long, L., Hawula, Z., Birch, S., Wyche, P., Gandhi, M. K. and Keane, C. (2023). Gene expression and spatial transcriptomic analysis of paired diagnosis and relapse DLBCL biopsies show a reduction in T cell infiltration and function at relapse. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_191
Tobin, J. W., Tsang, H., Patch, A., Keane, C., Law, S. C., Gunawardana, J., Blombery, P., Thompson, E. R., Sabdia, M. B., De Long, L. M., Nath, K., Kazakoff, S. H., Cheah, C., Amanuel, B., Cochrane, T., Butler, J., Johnston, A., Shanavas, M., Li, L., Shelton, V., Hershenfeld, S., Kridel, R., Seymour, J. F., MacManus, M. and Gandhi, M. K. (2023). Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_189
Shaw, B., Chung, E., Wellard, C., Yoo, E., Bennett, R., Birks, C., Johnston, A., Cheah, C., Hamad, N., Simpson, J., Barraclough, A., Ku, M., Viiala, N., Ratnasingam, S., Armytage, T., Cochrane, T., Chong, G., Lee, D., Manos, K., Keane, C., Wallwork, S., Opat, S. and Hawkes, E. (2023). Polatuzumab, Bendamustine & Rituximab Efficacy In Relapsed/refractory Trial‐ineligible Large B Cell Lymphoma Patients: An Australian Lymphoma Registry (LARDR) Study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3165_572
Lavie, D., Johnson, N., Borchmann, P., Herrera, A. F., Avigdor, A., Gasiorowski, R., Gregory, G., Keane, C., Vucinic, V., Bazargan, M., Herishanu, Y., Minuk, L., Tzoran, I., Andreadis, C., Armand, P., Kuruvilla, J., Zinzani, P. L., West, R. Marceau, Pillai, P., Marinello, P. and Timmerman, J. (2023). An open‐label phase 1/2 study of favezelimab plus pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma with/without previous anti‐PD‐1 treatment. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_263
Hawkes, E. A., Palmer, J., Chong, G., Lee, S., Keane, C., Shortt, J., Scott, A. M., Churilov, L., Macmanus, M., Smith, C., Barraclough, A., Khor, R. and Manos, K. (2023). Radiotherapy (RT) & Durvalumab in Relapsed/Refractory Diffuse Large B‐cell Lymphoma (DLBCL) & Follicular Lymphoma (FL). The phase I “RaDD” study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_448
Koldej, R. M., Barraclough, A., Lee, S. T., Morgan, H., Holzwart, N., Koshy, M., Smith, C., Chong, G., Gilbertson, M., Keane, C., Ting, S., Churilov, L., Ritchie, D. S. and Hawkes, E. A. (2023). T cell CD62L expression following nivolumab therapy is associated with response to rituximab‐nivolumab in treatment naïve follicular lymphoma: the 1st FLOR study. 17th International Conference on Malignant Lymphoma, Lugano, Switzerland, 13 - 17 June 2023. Chichester, West Sussex United Kingdom: Wiley-Blackwell. doi: 10.1002/hon.3164_183
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth P., Keane, Colm, Tsoran-Rosenthal, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, West, Rachel Marceau, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166670
Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth P., Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. 64th ASH Annual Meeting, New Orleans, LA United States, 10-13 December 2022. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2022-166846
Borchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash and Timmerman, John (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890812.66186.e8
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Tzoran, Inna, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Nahar, Akash and Herrera, Alex F. (2022). Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment. 12th International Symposium on Hodgkin Lymphoma, Cologne, Germany, 22-24 October 2022. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000890800.36906.bb
Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17
Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Inna, Tzoran, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Manos, Kate, Khor, Richard, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew M., Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Hawkes, Eliza (2021). Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia Pa, Apr 10-May 21, 2021. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.
Tsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954
Hawkes, Eliza Anne, Manos, Kate, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael Patrick, Keane, Colm, Scott, Andrew Mark, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison Anne, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2020). Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, May 29-31, 2020. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
Nath, Karthik, Law, Soi C., Sabdia, Muhammed B., De Long, Lilia Merida, Shanavas, Mohamed, Tobin, Joshua W. D., Gunawardana, Jay, Vari, Frank, Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Keane, Colm and Gandhi, Maher K. (2019). Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, 7 - 10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-130050
Hawkes, Eliza A., Manos, Kate, Chong, Geoff, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze-Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2019). y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL USA, 7-10 December 2019. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2019-122635
Gandhi, M.K., Hoang, T., Tobin, J.W., Law, S.C., Talaulikar, D., Jain, S., Vari, F., Murigneux, V., Fink, L., Gunawardana, J., Gould, C., Oey, H., Delecluse, S., Trappe, R.U., Merida de Long, L., Sabdia, M.B., Bhagat, G., Hapgood, G., Blyth, E., Clancy, L., Casey, J., Wight, J., Hawkes, E. and Keane, C. (2019). EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy. 15th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18–22 June 2019. Oxford, United Kingdom: John Wiley & Sons. doi: 10.1002/hon.91_2629
Gould, Clare, Keane, Colm, Murigneux, Valentine, Oey, Harald, Ellis, Jonathan, Birch, Simone, Gunawardana, Jay, Talaulikar, Dipti, Hertzberg, Mark S., Jones, Kimberley and Gandhi, Maher K. (2019). B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL. ASH Annual Meeting, Orlando, FL, United States, 7-10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-126537
Abro, Emad Uddin, Law, Soi C., Keane, Colm, Birch, Simone, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Johnson, Peter, Trotman, Judith, Berkahn, Leanne, Fulham, Michael, Anderson, Richard A., Saunderson, Anne L., Gunawardana, Jay, Cross, Donna, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Law, W. P., Gill, Devinder and Gandhi, Maher K. (2018). A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial. 60th ASH Annual Meeting, San Diego, CA United States, 1-4 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-112008
Keane, Colm, Law, Soi C., Gould, Clare, Francis, Santiyagu, Abro, Emad Uddin, Tobin, Joshua W. D., Birch, Simone, Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Talaulikar, Dipti, Gill, Anthony, Jain, Sanjiv, Cross, Donna, Hernadez, Annette, Halliday, Sarah-Jane, Bird, Robert, Hertzberg, Mark and Gandhi, Maher K. (2018). Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, United States, 1-4 December 2018. Washington, DC, Untied States: American Society of Hematology. doi: 10.1182/blood-2018-99-112830
Tobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826
Gunawardana, Jay, Bednarska, Karolina, Law, Soi C., Lee, Justina, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Birch, Simone, Keane, Colm and Gandhi, Maher K. (2018). The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego CA, United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-115836
Tobin, Joshua W. D., Keane, Colm, Mollee, Peter, Birch, Simone, Gould, Clare, Gunawardana, Jay, Hoang, Thanh , Ma, Ti, Abro, Emad Uddin, Shanavas, Mohamed, Yoo, Hyung, Li, Li, Scuffham, Paul, Murigneux, Valentine, Fink, Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu and Gandhi, Maher K. (2017). The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V130.Suppl_1.728.728
Tobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.
Gandhi, Maher K., Keane, Colm, Tobin, Joshua W. D., Talaulikar, Dipti, Jain, Sanjiv, Vari, Frank, Kruze, Lutz, Murigneux, Valentine, Fink, Lynn, Gunawardana, Jithendra, Gould, Clare, Oey, Harold, Fink, Susanne, Trappe, Ralf Ulrich, Mathews, Marina, Francis, Santiyagu and Hoang, Thanh (2017). The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA, United States, 9-12 December 2017. Washington, DC, United States: American Society of Hematology.
Shanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.
Gandhi, Maher K., Arpon, David, Keane, Colm, Han, Erica, Tobin, Josh, Bird, Robert, Hertzberg, Mark S., Self, Marlene, Cross, Donna, Hernandez, Annette and Vari, Frank (2016). A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego CA, United States, 3-6 December 2016. Washington, DC United States: American Society of Hematology.
Keane, Colm, Jones, Kimberly, Gould, Clare, Hamm, David, Wood, Peter, Birch, Simone, Crooks, Pauline, Green, Michael R., Taulaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL). 55th Annual Meeting and Exposition of the American-Society-of-Hematology, New Orleans, LA, United States, 7-10 December 2013. WASHINGTON: AMER SOC HEMATOLOGY.
Lecao K.-A., Keane C., Han E., Talaulikar D. and Gandhi M. (2015). Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios. Scientific Stream at Big Data in Health Analytics 2015, BigData 2015, Sydney; Australia, October 20, 2015-October 21, 2015. Aachen, Germany: Rheinisch-Westfaelische Technische Hochschule Aachen.
Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology.
Kurtz, David Matthew, Green, Michael R., Bratman, Scott Victor, Liu, Chih-Long, Glover, Cynthia, Keane, Colm, Kong, Katie, Faham, Malek, Miklos, David Bernard, Advani, Ranjana H., Levy, Ronald, Hertzberg, Mark S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. 50th Annual Meeting of the American Society of Clinical Oncology, Chicago IL United States, May 30-June 3, 2014. Alexandria VA, United States: American Society of Clinical Oncology.
Gandhi, Maher K., Vari, Frank, Crooks, Pauline, Keane, Colm, Nourse, Jamie P., Seymour, Louise A., Ritchie, David, Gottlieb, David, Gill, Devinder and Jones, Kimberley (2012). Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta GA, United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology.
Gandhi, MK, Hertzberg, MS, Han, E, Seymour, JF, Hicks, R, Gill, DS, Keane, C, Crooks, P, Radford, K and Vari, F (2011). Monocytes Are Associated with Impaired T-Cell Immunity and Residual Interim-PET/CT Avidity After 4 Cycles of CHOP-R In Patients with High-Risk DLBCL. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.
Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.
Keane, C., Shen, L., Nourse, J., Han, E., Jones, K. and Gandhi, M. (2011). Tissue microarray in DLBCL patients receiving CHOP-R chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6 and poor outcome for EBER-ISH positive patients. 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 15-18 June 2011. Oxford, United Kingdom: Oxford University Press.
Gandhi, M., Keane, C., Nourse, J., Jones, K., Ross, N., Han, E. and Nguyen-Van, D. (2010). Ebv-Positive Dlbcl of the Elderly Is a Distinct Clinico-Biological Entity with Poor Outcome in Chop-R Treated Patients. 15th Annual Meeting of the European-Hematology-Association, Barcelona Spain, June 10-13, 2010. Pavia, Italy: Fondazione Ferrata Storti.
McHugh, Johnny, O'Ceallaigh, Cathal, Keane, Colm, Otridge, Brian W. and O'Gorman, Peter (2006). Thalidomide and dexamethasone in newly diagnosed multiple myeloma. 48th Annual Meeting of the American Society of Hematology, Orlando, FL, United States, 9-12 December 2006. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V108.11.5120.5120
McHugh, Johnny, Keane, Colm, Otridge, Brian W., Thornton, Patrick and O'Gorman, Peter (2005). Thalidomide and dexamethasone in newly diagnosed multiple myeloma. 47th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA, United States, 10-13 December 2005. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V106.11.5185.5185
Mills, AK, Gibbs, S, Keane, C, Mollee, P, Grimmett, K, Van Kuilenburg, R, Saal, R, Gill, D, Prince, HM, Seymour, JF and Marlton, P (2004). Optimal timing of peripheral blood stem cell mobilisation in patients with hematological malignancies treated with the hyper-CVAD chemotherapy regimen. 46th Annual Meeting of the American-Society-of-Hematology, San Diego Ca, Dec 04-07, 2004. WASHINGTON: AMER SOC HEMATOLOGY.